Epigenomics AG (FRA:ECX) Moat Score: 0/10 (As of Jul. 01, 2026)


FRA:ECX Epigenomics AG FRA:ECX
13 GF Score
Price €0.95
GF Value €0.09
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Moat Score?

Epigenomics AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Epigenomics AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Epigenomics AG might have No Moat - No discernible moat.

Epigenomics AG  (FRA:ECX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Epigenomics AG Moat Score Related Terms

FRA:ECX
13GF Score
Epigenomics AG FRA:ECX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Epigenomics AG (FRA:ECX) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €0.95 is trading 955.6% above its estimated GF Value™ of €0.09. GuruFocus considers Epigenomics AG to be Significantly Overvalued.

Key valuation signals for FRA:ECX:

  • Moat Score: 0
  • GF Value™: €0.09 vs. price of €0.95 (955.6% above fair value)
  • GF Score™: 13/100 with 3 warning signs

No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score

Get the complete analysis for FRA:ECX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€0.09
GF Value